Study to Investigate Luveltamab Tazevibulin in Adults with Advanced or Metastatic Non-small Cell Lung Cancer

Description

A Phase 2 study evaluating STRO-002 in subjects with previously treated advanced or metastatic non-small cell lung cancer expressing FOLR1

Conditions

Lung Cancer, Lung Cancer Metastatic, Lung Cancer, Nonsmall Cell, Lung Cancer Non-Small Cell Stage IIIB, Lung Cancer Non-small Cell Stage IV, Lung Cancer, Non-small Cell

Talk to us

Study Overview

On this page

Study Details

Study overview

A Phase 2 study evaluating STRO-002 in subjects with previously treated advanced or metastatic non-small cell lung cancer expressing FOLR1

A Phase 2, Open-label Study Evaluating STRO-002, an Anti-folate Receptor Alpha (FOLR1) Antibody-Drug Conjugate, in Subjects with Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer Expressing FOLR1

Study to Investigate Luveltamab Tazevibulin in Adults with Advanced or Metastatic Non-small Cell Lung Cancer

Condition
Lung Cancer
Intervention / Treatment

-

Contacts and Locations

Lake Mary

Florida Cancer Specialists, Lake Mary, Florida, United States, 32746

Tampa

Tampa General Hospital, Tampa, Florida, United States, 33606

St. Paul

HealthPartners Cancer Research Center, St. Paul, Minnesota, United States, 55101

Dallas

Mary Crowley Cancer Research, Dallas, Texas, United States, 75230

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Histologically or cytologically confirmed non-squamous/adenocarcinoma or adenosquamous NSCLC that is either unresectable Stage IIIb/c disease not amenable for definitive chemoradiation, or Stage IV.
  • * Age ≥ 18 years
  • * ECOG performance status 0 to 1.
  • * Received at least 2 but no more than 4 prior lines of systemic therapy for advanced NSCLC
  • * Disease progression during or following the most recent systemic anti-cancer therapy.
  • * Positive FOLR1 expression per central testing
  • * At least 1 measurable target lesion per RECIST 1.1
  • * Adequate organ function
  • * Prior treatment with a FOLR1- targeting ADCs or with ADCs that contain a tubulin inhibitor
  • * Untreated central nervous system metastases
  • * Ongoing immunosuppressive therapy, except for treated brain metastases, per criterion above.
  • * History of severe allergic or anaphylactic reactions to monoclonal antibody therapy or to antibody-related fusion protein treatment
  • * Pre-existing clinically significant ocular disorders, severe chronic obstructive pulmonary disease or asthma, clinically significant cardiac or cerebrovascular disease, or other significant concurrent, uncontrolled medical condition
  • * Previous solid organ transplantation
  • * Concurrent participation in another therapeutic treatment trial

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Sutro Biopharma, Inc.,

Study Record Dates

2026-10